|
Re: Not much encouragement today
|
5
|
Resverlogix Corp.
|
Jan 21, 2022 07:18PM
|
|
Re: Eversana ValuationCaseStudy
|
10
|
Resverlogix Corp.
|
Jan 09, 2022 12:37PM
|
|
Re: Eversana ValuationCaseStudy
|
9
|
Resverlogix Corp.
|
Jan 08, 2022 01:18PM
|
|
Re: Eversana ValuationCaseStudy
|
10
|
Resverlogix Corp.
|
Jan 08, 2022 11:30AM
|
|
Re: Holly Smokes
|
7
|
Resverlogix Corp.
|
Dec 31, 2021 11:23AM
|
|
Re: Question for posters
|
4
|
Resverlogix Corp.
|
Dec 12, 2021 11:54AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
3
|
Resverlogix Corp.
|
Dec 03, 2021 09:03AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
3
|
Resverlogix Corp.
|
Nov 29, 2021 06:47PM
|
|
Re: Interesting.
|
4
|
Resverlogix Corp.
|
Nov 22, 2021 01:53PM
|
|
Re: Time keeps ticking
|
8
|
Resverlogix Corp.
|
Nov 19, 2021 10:29AM
|
|
Re: First Dosing v "Actively Recruiting" ?
|
7
|
Resverlogix Corp.
|
Nov 11, 2021 02:09PM
|
|
Re: First Dosing v "Actively Recruiting" ?
|
7
|
Resverlogix Corp.
|
Nov 11, 2021 09:57AM
|
|
Re: "Actively Recruiting" ?
|
6
|
Resverlogix Corp.
|
Nov 04, 2021 02:15PM
|
|
Re: Collaborating with the Supreme Council of the Arab-African Economy
|
5
|
Resverlogix Corp.
|
Nov 03, 2021 10:04AM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
1
|
Resverlogix Corp.
|
Nov 01, 2021 12:34PM
|
|
Re: Volume
|
1
|
Resverlogix Corp.
|
Nov 01, 2021 11:57AM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
10
|
Resverlogix Corp.
|
Nov 01, 2021 11:22AM
|
|
Re: Just so...
|
4
|
Resverlogix Corp.
|
Oct 25, 2021 05:32PM
|
|
Re: Just so...
|
5
|
Resverlogix Corp.
|
Oct 25, 2021 01:29PM
|
|
Re: Close competitor…
|
1
|
Resverlogix Corp.
|
Oct 21, 2021 10:59AM
|
